Zilovertamab (Synonyms: UC-961; Cirmtuzumab) |
| Catalog No.GC66327 |
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling[1].
Zilovertamab (25 and 50 µg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation[1].
Zilovertamab (50 µg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level[1].
Cell Proliferation Assay[1]
| Cell Line: | CaOV3, CaOV3CisR, PEO1, and PEO4 cells |
| Concentration: | 25 and 50 µg/mL |
| Incubation Time: | 72 hours |
| Result: | Reduced the proliferation of CaOV3, CaOV3CisR and PEO1. |
Western Blot Analysis[1]
| Cell Line: | CaOV3, CaOV3CisR, PEO1, and PEO4 cells |
| Concentration: | 50 µg/mL |
| Incubation Time: | 72 hours |
| Result: | Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *